ImpediMed

ImpediMed Days Payable Outstanding

The Days Payable Outstanding (DPO) of ImpediMed (IPD.AX) as of Nov 11, 2026 is 19.83. In the previous year, Days Payable Outstanding (DPO) was 220.79 — a change of -91.02% (lower).

Days Payable Outstanding

19.83

YoY

-91.02%

Last updated:

Days Payable Outstanding (DPO) of ImpediMed is 2026 19.83 . Days Payable Outstanding (DPO) of ImpediMed was 2025 220.79 . It decreases by -91.02% lower compared to the previous year.

The ImpediMed Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2019
608.14 AUD
Jan 1, 2020
37.48 AUD
Jan 1, 2021
22.95 AUD
Jan 1, 2022
40.26 AUD
Jan 1, 2023
19.78 AUD
Jan 1, 2024
304.44 AUD
Jan 1, 2025
220.79 AUD
Jan 1, 2026
19.83 AUD
The ImpediMed Days Payable Outstanding history
YEARDays Payable OutstandingYoY
19.83-91.02%
220.79-27.48%
304.44+1,438.80%
19.78-50.86%
40.26+75.42%
22.95-38.77%
37.48-93.84%
608.14-9.91%
675.03+28.56%
525.07+24.57%
421.49+35.18%
311.79+136.26%
131.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Days Payable Outstanding (DPO) of ImpediMed is 19.83 in 2026.

Days Payable Outstanding (DPO) of ImpediMed changed from 220.79 to 19.83, representing a -91.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) ImpediMed since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s ImpediMed with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ImpediMed

All Key Metrics — ImpediMed